Dicerna Pharmaceuticals, Inc., a Watertown, Massachusetts-based RNAi-focused biopharmaceutical company developing novel therapeutic agents and related drug delivery systems in multiple disease areas utilizing its proprietary Dicer Substrate Technology™ and Dicer Substrate siRNA (DsiRNA) molecules, has closed a $25m Series B round of financing.
The round was led by new investor Domain Associates, with participation from existing investors Oxford Bioscience Partners, Skyline Ventures and Abingworth.
In conjunction with the financing, Domain Associates’ partner Brian K. Halak, Ph.D., joins the company’s board of directors.
The funds will be used to advance Dicerna’s lead in-house program in oncology towards clinical development and progress its other preclinical programs. The company also plans to use the capital to continue to develop conjugated drug delivery systems, which combine Dicerna’s DsiRNA molecules with targeting moieties such as peptides, aptamers or antibodies, potentially allowing for direct delivery into specific cells of interest.